Blue Earth Diagnostics to Showcase Molecular Imaging Advances at SNMMI 2026
Blue Earth Diagnostics will present new molecular imaging data focused on prostate cancer at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place May 30 to June 2, 2026.
The company, a Bracco company specializing in diagnostic radiopharmaceuticals, announced that nine abstracts have been accepted for presentation during the meeting. According to the company, the presentations will feature findings related to its PSMA PET imaging agent POSLUMA® (flotufolastat F 18) and Axumin® (fluciclovine F 18), with data spanning clinical and preclinical investigations.
Blue Earth Diagnostics said the accepted abstracts will explore “advancing clinical and preclinical evidence supporting novel PET imaging agents designed to improve prostate cancer detection,” including studies from an intra-patient, head-to-head comparison of POSLUMA® and piflufolastat F 18.
Across multiple studies, the company reported that POSLUMA demonstrated “strong performance in detecting biochemical recurrence following radical prostatectomy,” particularly at low prostate-specific antigen (PSA) levels where conventional imaging can face diagnostic limitations.
Additional presentations will examine the clinical utility of Axumin® in patients with negative or inconclusive PSMA PET scans. Blue Earth Diagnostics stated that the imaging agent “may uncover clinically significant lesions in patients with negative or inconclusive PSMA PET scans,” potentially helping physicians identify disease recurrence with greater confidence.
“SNMMI showcases our commitment to advancing nuclear medicine and enhancing patient outcomes through cutting-edge molecular imaging solutions, which facilitate precise, timely, and confident clinical decision-making,” said Chris Behmgoots, senior vice president and SNMMI showcase committee co-chair for Blue Earth Diagnostics.
The company noted that the research aims to support improved diagnostic pathways and treatment planning for prostate cancer patients, particularly in settings where recurrence detection remains challenging.
Further details regarding the scientific sessions and accepted abstracts are expected to be available through the official SNMMI meeting program.